The Food and Drug Administration on Friday expanded the approval of Vascepa, a fish-oil-derived medicine, to allow the drug’s maker to say it prevents heart attacks, strokes, and related health problems in people who are at high cardiovascular risk.

The approval reverses decades of mixed results for fish-oil-based drugs and could result in Vascepa being prescribed to millions of patients, potentially resulting in a windfall for the drug’s maker, Amarin Pharmaceuticals, which sells no other products.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Which species of fish is/are used in this drug Vascepa? Is there a risk of yeast or fungal contamination?

    • Ha, ha, my thoughts exactly! I notice the article uses relative risk and doesn’t mention whether this treatment actually extends life, but we do get an important clue:

      “all the outcomes were lumped together for statistical power.”

      A giant red flag but the FDA is color blind so it’s all good…

    • Your just mad because you are short the stock and now stuck. The drug is a good one, it works and it has brought my TGL down from 300 to 160 in 1 year.

    • one more Wall Street scam!!! under trump they will flood the market with wonder drugs the era of greed is just starting under this clown>

    • @JOEL unlike you, clearly being an Amarin stock holder making up claims, I am just a scientist looking at it for what it is.
      BTW, if what you say was demonstrably true, Vascepa would have been approved years ago, with much smaller and shorter trials.
      Instead, not only they didn’t use the right placebo, that is unrefined fish oil, to prove that their highly refined version has therapeutic effect as compared to over the counter products. They actually chronically poisoned the control group by administering them mineral oil, a substance rich in carcinogenic PAH. A substance under investigation by EFSA.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy